Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(18):1274; doi:10.1093/jnci/djj404
This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

In Brief

When Should You Get Screened for Cancer?

Most Americans don't know at what age they should start getting cancer screening tests, according to a new survey.

Researchers at the National Cancer Institute analyzed data from the Health Information National Trends Survey (HINTS), a telephone poll conducted in 2002–2003 and again in 2005. They found that 57% of American women do not know when they should start getting mammograms, 87% do not know they should receive an annual Pap test, and 54% do not know when they should start colorectal cancer screening.

Women Exposed to Diethylstilbestrol Have a Higher Risk of Breast Cancer

Women born to mothers who used the antimiscarriage drug diethylstilbestrol (DES) while pregnant are more likely to develop breast cancer, a new study shows.

Julie Palmer, Sc.D., of the Boston University School of Public Health, and colleagues examined information from 4,817 daughters exposed to DES and 2,073 not exposed. They found that daughters aged 40 or over who were exposed to DES had almost twice the risk of developing breast cancer.

The study was published in the August issue of Cancer Epidemiology, Biomarkers, and Prevention.

Anastrozole Safer Than Tamoxifen for Some Breast Cancer Patients

Postmenopausal women with early-stage breast cancer should be treated with anastrozole rather than tamoxifen, a new study suggests.

The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to examine the use of anastrozole and tamoxifen in more than 6,000 postmenopausal breast cancer patients. Researchers collected data over 5 years.

They found that patients taking anastrozole had fewer negative side effects and were less likely to stop treatment. These patients also had a better risk benefit profile, an assessment that examines the likelihood of cancer recurrence and treatment side effects.

The study was published in the August issue of Lancet Oncology.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Extract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?